Riluzole in the treatment of autism
Phase 2
- Conditions
- Childhood autism.Childhood autism
- Registration Number
- IRCT201107281556N27
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Inclusion Criteria: 1-DSM IV clinical diagnosis of autistic disorder, 2-children between the ages of 3 and 12 years ,3- presence of behavioral problems such as aggression, overactivity or repetitive behaviors (indication of treatment with risperidone)
Exclusion Criteria
1- Presence of any active medical problem, 2-any diagnosis in Axis I and II except for mental retardation, 3-history of allergy to Riluzole,4- receiving any psychotropic medications during past six weeks prior to the trial, 5-presence of hepatic disease, 6-history of seizure
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Severity of Autism. Timepoint: Baseline and weeks 5, and 10 after the begining of the treatment. Method of measurement: Aberrant Behavior Checklist-Community (ABC-C) Rating Scale.;Clinical Global Impression. Timepoint: Baseline and weeks 5, and 10 after the begining of the treatment. Method of measurement: CGI.
- Secondary Outcome Measures
Name Time Method